Growth Hormone Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major growth hormone deficiency markets reached a value of US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.
The growth hormone deficiency market has been comprehensively analyzed in IMARC's new report titled "Growth Hormone Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Growth hormone deficiency refers to a medical condition that develops when the pituitary gland in the brain fails to produce sufficient growth hormone to support normal growth and development. This hormone is essential for stimulating bone and tissue growth, increasing muscle mass, and regulating metabolism. In children, the condition can lead to delayed growth and short stature, as well as other physical and developmental problems. While in adults, deficiency of growth hormone can cause increased body fat, reduced muscle mass and bone density, compromised metabolism, etc. Individuals suffering from this disorder may also experience low self-esteem, depression, sensitivity to hot or cold temperatures, lack of concentration, poor memory, etc. The diagnosis of growth hormone deficiency typically requires an evaluation of the patient’s symptoms, medical history, and laboratory tests. The healthcare professional can also suggest a blood workup to measure protein levels in patients. Additionally, numerous imaging studies, like X-rays and MRI, are recommended to provide a detailed examination of the brain.
The increasing incidences of brain tumors that can affect the pituitary gland or the hypothalamus region, reducing their ability to produce or release growth hormone, are primarily driving the growth hormone deficiency market. In addition to this, the rising prevalence of various associated risk factors, such as infections, severe head injuries, radiation treatments, etc., is also bolstering the market growth. Furthermore, the widespread adoption of recombinant human growth hormone injections for treating the disease is acting as another significant growth-inducing factor. These hormone injections help to maintain normal body metabolism and structure in patients, improving emotional control and well-being. Additionally, numerous key players are making substantial investments in research initiatives to launch a needle-free drug delivery system, which can reduce administration discomfort in patients. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of advanced formulations delivered via the subcutaneous route, owing to its numerous advantages, such as long-lasting action in the body and enabling weekly injections instead of daily doses, is expected to drive the growth hormone deficiency market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the growth hormone deficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for growth hormone deficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the growth hormone deficiency market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the growth hormone deficiency market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the growth hormone deficiency market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current growth hormone deficiency marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the growth hormone deficiency market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the growth hormone deficiency market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the growth hormone deficiency market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of growth hormone deficiency across the seven major markets?
What is the number of prevalent cases (2018-2034) of growth hormone deficiency by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of growth hormone deficiency by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with growth hormone deficiency across the seven major markets?
What is the size of the growth hormone deficiency patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of growth hormone deficiency?
What will be the growth rate of patients across the seven major markets?
Growth Hormone Deficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for growth hormone deficiency drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the growth hormone deficiency market?
What are the key regulatory events related to the growth hormone deficiency market?
What is the structure of clinical trial landscape by status related to the growth hormone deficiency market?
What is the structure of clinical trial landscape by phase related to the growth hormone deficiency market?
What is the structure of clinical trial landscape by route of administration related to the growth hormone deficiency market?
The growth hormone deficiency market has been comprehensively analyzed in IMARC's new report titled "Growth Hormone Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Growth hormone deficiency refers to a medical condition that develops when the pituitary gland in the brain fails to produce sufficient growth hormone to support normal growth and development. This hormone is essential for stimulating bone and tissue growth, increasing muscle mass, and regulating metabolism. In children, the condition can lead to delayed growth and short stature, as well as other physical and developmental problems. While in adults, deficiency of growth hormone can cause increased body fat, reduced muscle mass and bone density, compromised metabolism, etc. Individuals suffering from this disorder may also experience low self-esteem, depression, sensitivity to hot or cold temperatures, lack of concentration, poor memory, etc. The diagnosis of growth hormone deficiency typically requires an evaluation of the patient’s symptoms, medical history, and laboratory tests. The healthcare professional can also suggest a blood workup to measure protein levels in patients. Additionally, numerous imaging studies, like X-rays and MRI, are recommended to provide a detailed examination of the brain.
The increasing incidences of brain tumors that can affect the pituitary gland or the hypothalamus region, reducing their ability to produce or release growth hormone, are primarily driving the growth hormone deficiency market. In addition to this, the rising prevalence of various associated risk factors, such as infections, severe head injuries, radiation treatments, etc., is also bolstering the market growth. Furthermore, the widespread adoption of recombinant human growth hormone injections for treating the disease is acting as another significant growth-inducing factor. These hormone injections help to maintain normal body metabolism and structure in patients, improving emotional control and well-being. Additionally, numerous key players are making substantial investments in research initiatives to launch a needle-free drug delivery system, which can reduce administration discomfort in patients. This, in turn, is also creating a positive outlook for the market. Moreover, the emerging popularity of advanced formulations delivered via the subcutaneous route, owing to its numerous advantages, such as long-lasting action in the body and enabling weekly injections instead of daily doses, is expected to drive the growth hormone deficiency market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the growth hormone deficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for growth hormone deficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the growth hormone deficiency market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the growth hormone deficiency market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the growth hormone deficiency market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current growth hormone deficiency marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the growth hormone deficiency market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the growth hormone deficiency market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the growth hormone deficiency market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of growth hormone deficiency across the seven major markets?
What is the number of prevalent cases (2018-2034) of growth hormone deficiency by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of growth hormone deficiency by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with growth hormone deficiency across the seven major markets?
What is the size of the growth hormone deficiency patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of growth hormone deficiency?
What will be the growth rate of patients across the seven major markets?
Growth Hormone Deficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for growth hormone deficiency drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the growth hormone deficiency market?
What are the key regulatory events related to the growth hormone deficiency market?
What is the structure of clinical trial landscape by status related to the growth hormone deficiency market?
What is the structure of clinical trial landscape by phase related to the growth hormone deficiency market?
What is the structure of clinical trial landscape by route of administration related to the growth hormone deficiency market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GROWTH HORMONE DEFICIENCY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GROWTH HORMONE DEFICIENCY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GROWTH HORMONE DEFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 GROWTH HORMONE DEFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GROWTH HORMONE DEFICIENCY - UNMET NEEDS
10 GROWTH HORMONE DEFICIENCY - KEY ENDPOINTS OF TREATMENT
11 GROWTH HORMONE DEFICIENCY - MARKETED PRODUCTS
11.1 List of Growth Hormone Deficiency Marketed Drugs Across the Top 7 Markets
11.1.1 Humatrope (Somatropin) - Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Macrilen (Macimorelin) - AEterna Zentaris
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 NutropinAq (Somatropin) - Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zomacton (Somatropin) - Ferring Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Sogroya (Somapacitan) - Novo Nordisk
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 GROWTH HORMONE DEFICIENCY - PIPELINE DRUGS
12.1 List of Growth Hormone Deficiency Pipeline Drugs Across the Top 7 Markets
12.1.1 LUM 201 - Lumos Pharma/Merck
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 GX H9 - Genexine/Handok
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. GROWTH HORMONE DEFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GROWTH HORMONE DEFICIENCY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GROWTH HORMONE DEFICIENCY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Growth Hormone Deficiency - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Growth Hormone Deficiency - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Growth Hormone Deficiency - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Growth Hormone Deficiency - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Growth Hormone Deficiency - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Growth Hormone Deficiency - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Growth Hormone Deficiency - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Growth Hormone Deficiency - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Growth Hormone Deficiency - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Growth Hormone Deficiency - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Growth Hormone Deficiency - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Growth Hormone Deficiency - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Growth Hormone Deficiency - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Growth Hormone Deficiency - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Growth Hormone Deficiency - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Growth Hormone Deficiency - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Growth Hormone Deficiency - Access and Reimbursement Overview
16 GROWTH HORMONE DEFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GROWTH HORMONE DEFICIENCY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GROWTH HORMONE DEFICIENCY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GROWTH HORMONE DEFICIENCY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GROWTH HORMONE DEFICIENCY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GROWTH HORMONE DEFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 GROWTH HORMONE DEFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GROWTH HORMONE DEFICIENCY - UNMET NEEDS
10 GROWTH HORMONE DEFICIENCY - KEY ENDPOINTS OF TREATMENT
11 GROWTH HORMONE DEFICIENCY - MARKETED PRODUCTS
11.1 List of Growth Hormone Deficiency Marketed Drugs Across the Top 7 Markets
11.1.1 Humatrope (Somatropin) - Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Macrilen (Macimorelin) - AEterna Zentaris
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 NutropinAq (Somatropin) - Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zomacton (Somatropin) - Ferring Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Sogroya (Somapacitan) - Novo Nordisk
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 GROWTH HORMONE DEFICIENCY - PIPELINE DRUGS
12.1 List of Growth Hormone Deficiency Pipeline Drugs Across the Top 7 Markets
12.1.1 LUM 201 - Lumos Pharma/Merck
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 GX H9 - Genexine/Handok
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. GROWTH HORMONE DEFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GROWTH HORMONE DEFICIENCY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GROWTH HORMONE DEFICIENCY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Growth Hormone Deficiency - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Growth Hormone Deficiency - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Growth Hormone Deficiency - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Growth Hormone Deficiency - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Growth Hormone Deficiency - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Growth Hormone Deficiency - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Growth Hormone Deficiency - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Growth Hormone Deficiency - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Growth Hormone Deficiency - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Growth Hormone Deficiency - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Growth Hormone Deficiency - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Growth Hormone Deficiency - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Growth Hormone Deficiency - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Growth Hormone Deficiency - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Growth Hormone Deficiency - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Growth Hormone Deficiency - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Growth Hormone Deficiency - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Growth Hormone Deficiency - Access and Reimbursement Overview
16 GROWTH HORMONE DEFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GROWTH HORMONE DEFICIENCY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GROWTH HORMONE DEFICIENCY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
